ASCO 2015 Highlights

“These results support the promise of using cfDNA-based assays to develop an early cancer detection test with high specificity,” says Geoffrey R. Oxnard, MD.

“This is the first and largest study that shows that matching treatments to genetic mutations in tumors in patients with advanced cancer improves survival,” according to Catherine S. Magid Diefenbach, MD.

Chicago, IL—Lisocabtagene maraleucel (liso-cel), an investigational CD19-directed chimeric antigen receptor (CAR) T-cell therapy, has induced durable responses in high-risk patients with ag­gressive relapsed or refractory non-Hodg­kin lymphoma (NHL), according to data presented at ASCO 2018.

“We are confident that this will mark the first steps toward a reduction of the duration of trastuzumab in many women with HER2-positive breast cancer,” says Helena M. Earl, MBBS, PhD, FRCP.

“Treating financial toxicity at the patient level is similar to treating a symptom like fatigue. You can try to prevent it, but to some degree, patients are going to experience it, and when they do, you need a plan,” says Yousuf Zafar, MD, MHS.

Interest in personalizing medicine in oncology is growing, so the American Society of Clinical Oncology (ASCO) titled its theme for the 2018 presidential address at the annual meeting, "Delivering Discoveries: Expanding the Reach of Precision Medicine."

San Francisco, CA—Understanding the complex relationship between the PD-1 receptor, its ligand 1 (PD-L1), and mismatch repair deficiency (dMMR) status may help to improve treatment outcomes in patients with resectable gastric and esophageal cancer, according to a retrospective tissue-based analysis.